Am I wrong to read this as a reference to Fusion (a recent US$1.4billion buyout by Astra Zeneca)!"... Alpha-emitter therapies, such as those involving actinium-225 (Ac-225or 225Ac) and lead-212 (Pb-212 or 212Pb), are generatinginterest,BUT;
a) Their commercialsupply chains are still in the early development phase, and they arecurrently very difficult to source.
b) They are YET TOSHOWsafety and efficacy in late-stage trials, as opposed to betaemitters, like Cu-67, that have a long history of effectiveness in treatingsolid tumors...."
If so (and I think it is) - GREAT!
Ann: Clarity enters into Clinical Supply Agreement, page-5
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.18 |
Change
0.110(2.70%) |
Mkt cap ! $1.300B | |||
| Open | High | Low | Value | Volume |
| $4.11 | $4.20 | $4.07 | $1.952M | 469.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 5574 | $4.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.19 | 3985 | 10 |
View Market Depth
| Last trade - 14.23pm 23/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$4.18 |
Change
0.110 ( 2.94 %) |
||||
| Open | High | Low | Volume | ||
| $4.11 | $4.21 | $4.10 | 30467 | ||
| Last updated 14.35pm 23/05/2024 ? | |||||
| CU6 (ASX) Chart |